Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
HSP90 Inhibitor
HSP90i is a potent inhibitor of the heat shock protein 90 (HSP90), a key molecular chaperone involved in the stabilization and folding of client proteins. This compound demonstrates significant biological activity relevant to cancer research and therapeutic applications, particularly in the development of targeted therapies. HSP90i can also serve as an important intermediate for synthesizing ligand-mediated targeted protein degradation agents, such as dPDL1-4, facilitating advancements in targeted drug delivery systems. -
HSP Inhibitor
STA-2842 is a selective inhibitor of heat shock protein HSP90, demonstrating potential therapeutic effects in the context of autosomal dominant polycystic kidney disease (ADPKD). By modulating signaling pathways activated by mutations in PKD1 or PKD2 genes, STA-2842 effectively reduces renal cyst formation and inhibits kidney growth. In preclinical models, this compound has shown promise in slowing the progression of ADPKD, making it a valuable tool for understanding disease mechanisms and developing targeted interventions. -
HSP Inhibitor
17-GMB-APA-GA is a potent inhibitor of Heat Shock Protein 90 (HSP90), known for its role in protein folding and cellular stress responses. This compound is particularly useful in research focused on latent Toxoplasma gondii infections. Its ability to disrupt HSP90 function presents valuable opportunities for studying therapeutic strategies targeting this essential chaperone in infectious disease contexts. -
Hsp90 Inhibitor
HSP90-IN-14 is a potent inhibitor of heat shock protein 90 (Hsp90), exhibiting a dissociation constant (Kd) of 0.26 μM. This compound demonstrates significant antiviral activity against influenza viruses, showing EC50 values of 2.6 μM for A/H3N2, 3.9 μM for A/H1N1, and 17 μM for influenza B in MDCK cell assays. HSP90-IN-14 is a valuable tool for research into Hsp90's role in viral infections and therapeutic interventions. -
Hsp70 Inhibitor
YM-1 tosylate is a stable analog of MKT-077 that functions as an orally active inhibitor of Hsp70. This compound has been shown to induce cell death in HeLa cells, while also up-regulating p53 and p21 protein levels. YM-1 tosylate is valuable for research applications focused on cancer biology and cellular stress responses. -
HSP90 Inhibitor
DDO-6691 is a potent inhibitor of heat shock protein 90 (HSP90), targeting its role in protein folding and stabilization. This compound demonstrates significant antiproliferative activity against various tumor cell lines, particularly HCT-116 colon cancer cells, with an IC50 of 1.08 μM. DDO-6691 also effectively inhibits tumor growth in the HCT-116 xenograft mouse model, highlighting its potential for cancer research and therapeutic applications. -
HSP Inhibitor
Monorden diacetate is an effective Hsp90 inhibitor that demonstrates significant potential in the development of new fungicides. By targeting the heat shock protein 90 (HSP90), it disrupts the molecular chaperone activity essential for the stability and function of various client proteins. This compound is valuable for research applications focused on fungal biology and disease management. -
HSP Induction Inhibitor
NSC-134754 is a dehydroemetine derivative that functions as a heat shock protein induction inhibitor. It specifically targets Hsp72 and Hsp27 at the post-transcriptional level, without affecting overall protein synthesis, HSF-1 transcriptional activity, or Hsp mRNA levels. Preclinical studies indicate that NSC-134754 exhibits minimal toxicity while enhancing the sensitivity of cancer cells to proteasome and Hsp90 inhibitors. This reagent is applicable in research involving multiple myeloma, prostate carcinoma, and colon carcinoma. -
HSP90 Inhibitor
MPC-0767 is a selective and potent inhibitor of heat shock protein 90 (HSP90). As an L-alanine ester proagent of MPC-3100, it exhibits enhanced chemical stability, making it suitable for in vivo applications. MPC-0767 is primarily utilized in research applications focused on cancer biology, as it disrupts the chaperone function of HSP90 and thereby influences the stability of various oncogenic client proteins. -
Hsp90-TPR2A Interaction Inhibitor
Hsp90-IN-43 is a potent inhibitor of the Hsp90-TPR2A interaction, exhibiting an IC50 value of 360 nM and a Kd of 928 nM. This compound effectively inhibits the proliferation of BT474 breast cancer cells, making it a valuable tool for research in breast cancer biology. Its specific activity allows for deeper investigation into the role of Hsp90 in cancer progression and therapeutic response. -
Dye Tethered Hsp90 Inhibitor
HS-131 is a dye-tethered inhibitor that targets heat shock protein 90 (Hsp90). This compound exhibits the ability to selectively bind to and inhibit Hsp90, facilitating the detection of oncogene-driven breast cancers across various molecular subtypes. HS-131 is a valuable research tool for studying the role of Hsp90 in cancer biology and for developing novel therapeutic strategies targeting breast cancer. -
Hsp90α/Hsp90β Inhibitor
PU-11 is a selective inhibitor of Hsp90α and Hsp90β, targeting the ATP-binding pocket of these heat shock proteins. It exhibits IC50 values of 18.6 μM and 89.8 μM, along with Kd values of 2 μM for Hsp90α and 4.2 μM for Hsp90β, demonstrating a preference for Hsp90α due to the unique Ser52 residue. PU-11 is applicable in research related to neurodegenerative disorders, providing insights into the role of Hsp90 in cellular stress responses and protein homeostasis. -
HSP Inhibitor
HSP90-IN-28 is a selective inhibitor of heat shock protein 90 (Hsp90), demonstrating an IC50 value of 0.46 μM for Hsp90α and approximately 48-fold selectivity over Hsp90β (IC50 = 22.28 μM). This compound is instrumental in research focused on cellular stress responses, cancer biology, and protein homeostasis. Its specificity makes HSP90-IN-28 an effective tool for studying the role of Hsp90 in various physiological and pathological processes. -
FKBP51-Hsp90 Inhibitor
FKBP51-Hsp90-IN-2 is a selective inhibitor of the FKBP51-Hsp90 protein-protein interaction, demonstrating IC50 values of 0.4 µM for FKBP51 and 5 µM for FKBP52. This compound has been shown to enhance cellular energy metabolism and promote neurite growth. Its efficacy makes FKBP51-Hsp90-IN-2 a valuable tool in research focused on neurodegenerative diseases and cancer. -
MAO A/HSP90 Inhibitor
MAO A/HSP90-IN-1 is a dual inhibitor targeting MAO A and HSP90, exhibiting IC50 values of 1.77 μM in glioblastoma GL26 cells and 0.019 μM for HSP90α. This compound effectively inhibits MAO A activity, disrupts HSP90 binding, and downregulates HER2 and phospho-Akt expression, leading to reduced growth of glioblastoma cells. Additionally, MAO A/HSP90-IN-1 decreases PD-L1 expression, which may hinder tumor immune escape and suppress T cell activation. This reagent serves as a valuable tool for research on brain tumor-related diseases. -
HSP90 Inhibitor
HSP90-IN-29 is a selective inhibitor of heat shock protein 90 (HSP90), exhibiting a potent IC50 value of 30 nM. This benzoxazole derivative demonstrates significant antitumor activity, making it a valuable tool for cancer research. Its specific targeting of HSP90 allows for the exploration of its role in oncogenesis and the development of therapeutic strategies against malignancies. -
Hsp90 Inhibitor
HSP90-IN-35 is a selective Hsp90 inhibitor that exhibits potent antitumor activity, with an IC50 value for Her2 in the range of 0.05 to 0.5 μM. This compound is valuable for research applications focused on cancer biology and therapeutic development. Additionally, HSP90-IN-35 can be utilized in the synthesis of PROTACs, facilitating the exploration of targeted protein degradation strategies in cellular models. -
Hsp90 Inhibitor
C086 is a potent inhibitor of Heat Shock Protein 90 (Hsp90), a crucial chaperone involved in protein folding and stability. This compound has been shown to inhibit cell cycle progression and induce apoptosis across various cell types. It also exhibits anti-metastatic properties, making it a valuable tool for research in cancer biology and therapeutic development targeting Hsp90. -
HSP70 Inhibitor
HSP70-IN-5 is a selective inhibitor of the heat shock protein 70 (HSP70). It demonstrates an IC₅₀ of 0.6 μM in HSP70/DnaJ-mediated luciferase reconstitution assays. This compound serves as a valuable biochemical probe for investigating the functional role of HSP70 and its co-chaperone DnaJ in diverse biological processes, including protein folding and stress response pathways. -
Aha1-Hsp90 Complex Inhibitor
Hsp90-IN-34 is a potent inhibitor of the Aha1-Hsp90 chaperone complex, displaying a high affinity for Hsp90 and Aha1 with a dissociation constant (KDapp) of 23.5 µM. This compound interferes with the ATPase activity of Hsp90 by disrupting its interaction with Aha1, thereby influencing chaperone-mediated protein folding and stability. Hsp90-IN-34 is valuable for research into cancer biology and the modulation of protein homeostasis. -
HSP90 Inhibitor
ML189 is a selective inhibitor of HSP90, a critical chaperone involved in protein folding and stability. By disrupting HSP90 activity, ML189 induces the degradation of client proteins, which can affect cellular proliferation and survival. This compound is primarily utilized in research related to infectious diseases, including candidiasis, and provides insights into the role of HSP90 in pathogen biology and therapeutic development. -
HSP90 Inhibitor
ML229 is a high-affinity inhibitor of HSP90, a chaperone protein crucial for the stability and function of various client proteins. This compound demonstrates significant biological activity in modulating heat shock protein activity, making it a valuable tool for investigating the role of HSP90 in various cellular processes. ML229 has potential applications in the research of infectious diseases, including candidiasis, as it can interfere with the growth and survival of pathogenic organisms reliant on HSP90 for their virulence. -
HSP90 Inhibitor
BIIB-028 is an orally active inhibitor of heat shock protein 90 (Hsp90), primarily targeting its ATP-binding site. By disrupting Hsp90 function, BIIB-028 promotes the degradation of client proteins essential for cancer cell survival and proliferation. This compound is valuable for research in cancer biology and therapeutic development aimed at targeting Hsp90. -
Hsp70 Inhibitor
JG-48 is an inhibitor of the heat shock protein 70 (Hsp70), a molecular chaperone involved in protein folding and stabilization. This compound effectively reduces tau protein levels in various tauopathy models, making it a valuable tool for studying neurodegenerative diseases. Its specific targeting of Hsp70 provides insights into the role of protein aggregation in tau-related pathologies. -
HSP60 Inhibitor
DCEM1 is a potent inhibitor of heat shock protein 60 (HSP60), disrupting its interaction with ClpP and thereby impeding the mitochondrial unfolded protein response. This compound has been shown to significantly inhibit β-catenin expression and ATP production in both PC-3 and TKO cell lines. DCEM1 is a valuable tool for investigating the role of HSP60 in prostate cancer research and understanding its impact on cellular metabolism and signaling pathways. -
Hsp90 Inhibitor
BIIB021 mesylate is a potent inhibitor of the heat shock protein 90 (Hsp90). This orally active compound effectively inhibits the proliferation of chronic myeloid leukemia (CML) cells, demonstrating IC50 values of 513.99 nM for K562, 603.53 nM for K562/G, 110.08 nM for 32Dp210, and 148.07 nM for 32Dp210-T315I cell lines. BIIB021 promotes the degradation of the BCR-ABL protein and suppresses the β-catenin/c-Myc pathway, while also inducing autophagy in CML cells. This compound serves as a valuable tool for research focused on CML and Hsp90-related pathways. -
HSP90α Inhibitor
HSP90α-IN-1 is a selective inhibitor of HSP90α, with an IC50 value of 111 nM, demonstrating significant senolytic activity in diverse cellular senescence models. This compound is associated with the xanthinic family and plays a critical role in investigations aimed at addressing age-related inflammaging and associated diseases, including cancer. HSP90α-IN-1 is also being explored for its potential to promote healthy lifespan extension in various biological research contexts. -
Hsp90 Inhibitor
Pochonin D ((+)-Pochonin D) is a potent inhibitor of heat shock protein 90 (Hsp90) with demonstrated antiviral and anti-inflammatory activities. By targeting Hsp90, Pochonin D disrupts the proper folding, stabilization, and assembly of client proteins, including viral proteins, thereby impairing viral protein homeostasis and significantly reducing viral replication capacity. In addition, Pochonin D exhibits anti-inflammatory effects by attenuating inflammatory cell infiltration and suppressing the production of pro-inflammatory cytokines, such as TNF-α and IL-1β. These combined pharmacological properties highlight Pochonin D as a promising small-molecule tool for the study of human rhinovirus (HRV) infection and cancer-related pathways.
-
Hsp110-STAT3 Interaction Inhibitor
Hsp110-STAT3 PPI-IN-1 is a potent inhibitor of the Hsp110-STAT3 protein-protein interaction. This compound exhibits antiproliferative activity against the HPAEC cell line, demonstrating an IC50 value of 22.67 μM. It serves as a valuable tool for investigating the role of Hsp110-STAT3 interactions in various biological processes and therapeutic applications. -
HSP90 Inhibitor
KW-2478 hydrochloride is a potent HSP90 inhibitor with an IC50 value of 3.8 nM. It exhibits significant anti-proliferative effects by inducing apoptosis in chronic myeloid leukemia (CML) and liver cancer cells. KW-2478 hydrochloride disrupts the BCR/ABL and MAPK signaling pathways, resulting in elevated levels of p27 and p21, along with reduced cyclin B1 expression. Additionally, it downregulates STAT3 expression, making it a valuable tool for cancer research, particularly in the contexts of CML and liver malignancies. -
HSP90 Inhibitor
HSP90-IN-10 is a selective inhibitor of the heat shock protein 90 (HSP90) chaperone. It demonstrates significant antiproliferative activity against HCC1954 breast cancer cells, with an IC50 value of 6 µM, while sparing normal epithelial cells from growth inhibition. Additionally, HSP90-IN-10 promotes apoptosis, making it a valuable tool for research into cancer therapies targeting the HSP90 pathway. -
Hsp90 Inhibitor
CPUY201112 is a potent inhibitor of heat shock protein 90 (Hsp90), exhibiting a Kd of 27 nM. This compound induces p53-mediated apoptosis in MCF-7 cells, leading to cell cycle arrest. CPUY201112 is a valuable tool for cancer research, particularly in studies focusing on apoptosis pathways and cell cycle regulation. -
HSP70 Inhibitor
PET-16 is a selective HSP70 inhibitor that targets an allosteric site in the substrate-binding domain. By hindering the ATP-ADP cycling of HSP70, PET-16 effectively disrupts chaperone activity and promotes apoptosis, particularly in multiple myeloma cells. This compound is valuable for research focused on cancer biology, apoptosis mechanisms, and the role of heat shock proteins in disease progression. -
Hsp90 Inhibitor
WK88-1 is a potent inhibitor of Heat Shock Protein 90 (Hsp90), which promotes the degradation of various oncogenic signaling proteins, including EGFR, ErbB2, and ErbB3. This compound effectively induces growth arrest and apoptosis in the Gefitinib-resistant H1975 cell line. WK88-1 is valuable for research applications focused on cancer biology, particularly in studies targeting Hsp90-dependent pathways in drug-resistant tumor models. -
HSP90 Inhibitor
17-Demethoxy-reblastatin is a potent inhibitor of heat shock protein 90 (Hsp90), exhibiting an IC50 value of 1.82 μM for yeast Hsp90 ATPase activity. This compound effectively inhibits the proliferation of cancer cell lines, including HepG2 and SMMC7721, while also reducing colony formation. Additionally, it induces apoptosis through mitochondrial and caspase-mediated pathways, making it a valuable reagent for cancer research and therapeutic investigations targeting Hsp90 activity. -
Hsp90/HDAC6 Inhibitor
HDAC6/HSP90-IN-2 is a dual inhibitor targeting both HDAC6 and Hsp90, exhibiting IC50 values of 105.7 nM and 61 nM, respectively. This compound demonstrates significant potential in cancer research, enabling the study of mechanisms involved in tumorigenesis and the development of novel therapeutic strategies. Its ability to modulate key cellular pathways associated with cancer progression makes it a valuable tool for investigating the role of HDAC6 and Hsp90 in various malignancies. -
Hsp90 Inhibitor
HSP90-IN-18 is a potent inhibitor of heat shock protein 90 (Hsp90), exhibiting an IC50 value of 0.39 μM. This compound effectively disrupts Hsp90 function, making it valuable for research into viral infections, neurodegenerative diseases, and inflammatory conditions. Its capability to modulate Hsp90 activity provides a useful tool for studying the biological pathways influenced by this essential chaperone protein. -
Hsp90-Cdc37 PPI Inhibitor
Hsp90-Cdc37-IN-4 is a selective inhibitor of the Hsp90-Cdc37 protein-protein interaction (PPI). This compound disrupts the interaction by inhibiting casein kinase 2 (CK2), leading to reduced phosphorylation of Cdc37 at Serine 13. In cellular assays, Hsp90-Cdc37-IN-4 has been shown to induce G0/G1 cell cycle arrest and activate apoptotic pathways via the mitochondria. Additionally, it exhibits significant anti-breast cancer properties, making it a valuable tool in cancer research. -
HSP90 Inhibitor
HSP90-IN-13 is a potent inhibitor of Heat Shock Protein 90 (HSP90) with an IC50 of 25.07 nM. This compound exhibits multi-target activity, affecting key proteins such as Epidermal Growth Factor Receptor (EGFR), Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2), and Topoisomerase-2. HSP90-IN-13 promotes cell cycle arrest at the G2/M phase and induces apoptosis in MCF-7 cancer cells via a mitochondrial-mediated pathway, making it a valuable reagent for cancer research and therapeutic studies. -
HSP Inhibitor
Apatorsen sodium is a 2'-methoxyethyl-modified antisense oligonucleotide targeting Hsp27. It effectively reduces Hsp27 mRNA and protein levels, disrupting stress-induced cytoprotective functions, promoting apoptosis, inhibiting tumor growth, and preventing metastasis. This compound is relevant for research applications in non-small cell lung cancer, castration-resistant prostate cancer, breast cancer, ovarian cancer, and bladder cancer. -
Hsp90-Cdc37 PPI Inhibitor
DDO-5936 is a potent inhibitor of the Hsp90-Cdc37 protein-protein interaction. This compound specifically disrupts the chaperone-client complex, leading to altered protein folding and degradation pathways. Its biological activity makes DDO-5936 a valuable tool for research applications focused on colorectal cancer and other related therapeutic areas. -
HSPA5 Inhibitor
HM03 is a selective inhibitor of HSPA5 (Heat Shock Protein 70kDa, also known as Bip or Grp78). This compound exhibits significant anticancer activity, making it a valuable tool for cancer research. It can be utilized to study the role of HSPA5 in tumor progression and therapeutic resistance, providing insights into potential treatment strategies targeting this chaperone protein. -
Hsp90 Inhibitor
Zelavespib hydrochloride is a potent inhibitor of the heat shock protein 90 (Hsp90), exhibiting an IC50 of 51 nM in MDA-MB-468 cancer cell lines. This compound disrupts Hsp90 function, leading to the degradation of client oncoproteins, thereby demonstrating significant potential in cancer research. Zelavespib is utilized in studies focused on the therapeutic targeting of Hsp90 for various malignancies. -
Hsp70 Inhibitor
YM-1 is an orally active inhibitor of the heat shock protein 70 (Hsp70). This compound has been shown to induce apoptosis in HeLa cells while also up-regulating key regulatory proteins such as p53 and p21. Its effects on cell viability and protein expression make YM-1 a valuable tool for studying the role of Hsp70 in cancer biology and therapeutic applications. -
PfHsp90 Inhibitor
Ursolic acid acetate is a triterpenoid compound that inhibits Plasmodium falciparum heat shock protein 90 (PfHsp90) with a binding affinity (KD) of 8.16 μM. It exhibits cytotoxic effects on KB cells, with an IC50 value of 8.4 μM. This compound is suitable for applications in tumor research and antimalarial studies, providing a valuable tool for investigating the role of heat shock proteins in disease mechanisms. -
HSP70 Allosteric Inhibitor
MAL3-101 is a potent allosteric inhibitor of the heat shock protein 70 (HSP70), primarily acting by inhibiting the ATPase activity of HSP70 through disruption of the Hsp40 co-chaperone interaction. This compound has demonstrated significant biological activity in cellular models, making it a valuable tool for investigating the role of HSP70 in muscle invasive bladder cancer (MIBC) research. Researchers can utilize MAL3-101 to explore therapeutic strategies targeting this molecular chaperone in cancer treatment. -
HSP90 Inhibitor
Icapamespib hydrochloride is a selective inhibitor of HSP90, targeting epichaperome assembly with slow dissociation kinetics. This compound effectively disrupts disease-related protein interaction networks, reducing neurotoxic protein aggregation and hindering tumor cell survival signals. Icapamespib hydrochloride is valuable in research focused on neurodegenerative diseases, including Alzheimer's disease, along with various cancers, such as glioblastoma and metastatic breast cancer. -
HSP90 Inhibitor
Icapamespib is a selective inhibitor of HSP90 that effectively disrupts epichaperome formation through non-covalent binding, exhibiting slow dissociation kinetics. This compound is capable of crossing the blood-brain barrier, facilitating the disassembly of abnormal protein interaction networks and reducing neurotoxic protein aggregation. Icapamespib demonstrates potential in research applications focused on neurodegenerative diseases, including Alzheimer’s disease, as well as various cancers such as glioblastoma and metastatic breast cancer. -
Hsp90 Inhibitor
SNX-0723 is a potent Hsp90 inhibitor that exhibits anti-Plasmodium activity. It demonstrates notable binding affinity for human Hsp90 and Plasmodium falciparum Hsp90, with inhibition constants (Kis) of 4.4 nM and 47 nM, respectively. Additionally, SNX-0723 effectively inhibits liver-stage Plasmodium berghei ANKA parasites, with an EC50 value of 3.3 μM, making it a valuable tool for research into malaria treatment and Hsp90-related biological processes. -
HSP70 ATPase Inhibitor
Displurigen (NSC375009) is an HSP70 ATPase inhibitor that specifically targets HSPA8, disrupting the pluripotency of human embryonic stem cells. This compound effectively inhibits the ATPase activity of HSP70 with an IC50 of 225 μM, making it a valuable tool for research in stem cell biology and differentiation processes. Its mechanism of action provides insights into cellular signaling pathways related to stem cell maintenance and development.
